Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
125(c) 109.29(c) 105.72(c) 105.8(c) 97.82(c) Last
1 752 538 2 293 706 773 492 614 781 1 227 343 Volume
+7.66% -12.57% -3.27% +0.08% -7.54% Change
More quotes
Financials
Sales 2021 1 718 M 2 080 M 2 080 M
Net income 2021 1 109 M 1 343 M 1 343 M
Net cash position 2021 2 745 M 3 324 M 3 324 M
P/E ratio 2021 10,2x
Yield 2021 -
Sales 2022 6 831 M 8 271 M 8 271 M
Net income 2022 3 319 M 4 019 M 4 019 M
Net cash position 2022 6 287 M 7 612 M 7 612 M
P/E ratio 2022 3,41x
Yield 2022 -
Capitalization 17 754 M 21 497 M 21 497 M
EV / Sales 2021 8,74x
EV / Sales 2022 1,68x
Nbr of Employees 505
Free-Float 44,1%
More Financials
Company
CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies. 
Read more
More about the company
Ratings of CureVac N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CUREVAC N.V.
06/09EU, U.S. to agree reduction of vaccine export barriers, summit draft says
RE
06/04CUREVAC N  : CONVENING NOTICE (Form 6-K)
PU
06/02Germany to build up reserve vaccine capacity to fight future pandemics
RE
06/02CUREVAC N  : Appoints Klaus Edvardsen as Chief Development Officer (Form 6-K)
PU
06/02PRESS RELEASE : CureVac Appoints Klaus Edvardsen as Chief Development Officer
DJ
06/02CUREVAC N  : Appoints Klaus Edvardsen as Chief Development Officer
EQ
06/01CUREVAC N  : COVID-19 Vaccine Study Passes Interim Analysis by Data Safety Monit..
MT
05/28CUREVAC N  : First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Towa..
PU
05/28PRESS RELEASE : CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, C..
DJ
05/28CUREVAC N  : First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Towa..
EQ
05/27PRESS RELEASE : Novartis and Molecular Partners announce start of EMPATHY clinic..
DJ
05/26CUREVAC N  : Posts Wider Q1 Pre-Tax Loss, Revenue Rises
MT
05/26CUREVAC N  : Earnings Flash (CVAC) CUREVAC Posts Q1 Revenue EUR10M
MT
05/26CUREVAC N  : First preclinical data of second-generation COVID-19 vaccine candid..
PU
05/26PRESS RELEASE : CureVac Announces Financial -2-
DJ
More news
News in other languages on CUREVAC N.V.
06/11VACCINS : la directrice de l'EMA appelle à la solidarité internationale
06/11MÄRKTE USA/Börsen gehen etwas fester ins Wochenende - Dow bleibt zurück
06/11MÄRKTE USA/Börsen treten auf der Stelle
06/11MÄRKTE EUROPA/Börsen legen deutlicher zu - Banken bleiben zurück
06/11XETRA-SCHLUSS/Fester - Autowerte gesucht, Deutsche Bank fallen
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Analysis
EU, U.S. to agree reduction of vaccine export barriers, summit draft says
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 80,37 €
Last Close Price 80,79 €
Spread / Highest target 24,9%
Spread / Average Target -0,52%
Spread / Lowest Target -41,3%
EPS Revisions
Managers and Directors
NameTitle
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer
Baron Jean Stéphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CUREVAC N.V.20.66%21 497
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416